愛瑪客 ARMK 深 滬
等待開盤 01-30 09:30:00 美东时间
38.44
-0.060
-0.16%
華盛通- 最 高38.95
- 今 開38.95
- 成交量 66.23万股
- 最 低 38.38
- 昨 收 38.50
- 總市值 101.10亿
- 52周最高 44.265
- 市盈率 靜 31.49
- 換手率 0.25%
- 52周最低 29.59
- 委 比 -83.00%
- 總股本 2.63亿
- 歷史最高 44.265
- 量 比 0.59
- 振 幅 1.48%
- 歷史最低 -2.46
- 每 手 1
- 風險率 2.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
Morgan Stanley Maintains Equal-Weight on Aramark, Raises Price Target to $44
Morgan Stanley analyst Toni Kaplan maintains Aramark (NYSE:ARMK) with a Equal-Weight and raises the price target from $43 to $44.
2025-12-17 21:47
InvestorsTape.com- VENU and Live Nation Take the Big Stage
Venu Holding Corporation (VENU) has signed a transformative Operator Agreement with Live Nation, marking a significant step in its national expansion. Under the deal, Live Nation becomes the exclusive operator and booking agent for VENU's 20,000-capacity Sunset Amphitheater in McKinney, Texas. This partnership enhances VENU's growth trajectory, profitability, and financial visibility, leveraging Live Nation's global booking power and artist relat...
2025-12-12 15:13
美股大行评级 | 高盛上调百度、美敦力、晶科能源等多只个股目标价；家得宝遭9家机构下调目标价；
今日重点评级关注：富国银行：维持Annexon"超配"评级，目标价从14美元升至27美元；瑞穗：上调Relmada Therapeutics评级至"跑赢大市"，目标价从1美元升至10美元
2025-11-20 10:28
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
2025-11-19 11:01
Baird Maintains Outperform on Aramark, Lowers Price Target to $46
Baird analyst Andrew Wittmann maintains Aramark (NYSE:ARMK) with a Outperform and lowers the price target from $47 to $46.
2025-11-19 00:01
Why Is Aramark Stock Sinking Monday?
Aramark's stock (ARMK) fell after reporting lower fourth-quarter FY25 earnings, with revenue missing analyst estimates.
2025-11-17 22:55
Aramark's shares underwater as solid FQ4 results miss lofty estimates
Aramark (ARMK) shares are under pressure in early trading as fiscal fourth quarter results and profit guidance for the year did not meet Wall Street’s ambitious expectations for the food service and ...
2025-11-17 21:11
Aramark Sees FY2026 Adj EPS $2.18-$2.28 vs $1.90 Est; Sees Sales $19.550B-$19.950B vs $18.624B Est
Aramark (NYSE:ARMK) is looking for FY2026 Adj EPS of $2.18-$2.28 vs $1.90 analyst estimate. sees sales of $19.550 billion-$19.950 billion vs $18.624 billion analyst estimate.
2025-11-17 19:37
